 |
        |
John J. PacificoPresident and Chief Executive Officer Mr. Pacifico was appointed President and Chief Executive Officer of ORTHOCON®, Inc. in December, 2010. He was a member of ORTHOCON's founding investment team and, in 2007, joined the company to lead its corporate development and finance functions. As Vice President of Corporate Development, he led ORTHOCON's Series B financing and expanded both its technology rights and its intellectual property portfolio. In addition, Mr. Pacifico was responsible for the early strategic decisions regarding the company's transition to a commercial organization and, in 2009, was appointed Senior Vice President of Commercial Operations. In this capacity, Mr. Pacifico was responsible for the commercial launch of HEMASORB®, the company's first FDA-cleared product, and the identification and prioritization of ORTHOCON's pipeline products. Mr. Pacifico brings to ORTHOCON a strong company building background. He gained this experience as a former member of the healthcare venture capital investment team at Canaan Partners where he participated in over 25 biopharmaceutical and medical device company financings, initial public offerings, and acquisitions. Mr. Pacifico joined Canaan at age twenty and had the unique opportunity to be mentored by some of the world's leading venture capitalists and entrepreneurs during the dot-com era. As a company leader and investor, he worked with private and public company management teams that developed and brought to market several leading therapeutic drugs and medical devices, and created over $2 billion of company value. Mr. Pacifico earned a MBA from Columbia University and a BS in Finance from the Charles F. Dolan School of Business at Fairfield University where he was also a member of the varsity baseball team. Furthermore, Mr. Pacifico is an alumnus of the Kauffman Fellows Program, an educational program that identifies, develops, and networks the next generation of global leaders in venture capital. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
